SCODiA Report by MLBI Lab

Single-Cell Transcriptomic Analysis of Peripheral Blood Reveals Systemic Immune Dysregulation in Idiopathic Pulmonary Fibrosis Progression

This single-cell RNA sequencing analysis of peripheral blood reveals significant immune cell compositional and functional shifts in Idiopathic Pulmonary Fibrosis (IPF) patients, particularly those with progressive disease. Key findings include an expansion of monocytes and a reduction in naive T cells, alongside a distinct activation signature in progressive IPF characterized by exhausted CD8+ T cells (TIGIT+) and heightened pro-inflammatory cell-cell interactions. Enriched pathways indicate broad immune activation, enhanced cell migration, and metabolic reprogramming, collectively pointing to a systemic immune dysregulation that likely fuels disease progression.

Contents

  1. Dataset overview
  2. UMAP Visualization of Single-Cell Blood Transcriptome in Idiopathic Pulmonary Fibrosis
  3. UMAP Visualization of Major Cell Type Scores and Annotations
  4. Marker Expression Dot Plot for Cell Subsets
  5. Peripheral Blood Immune Cell Population Shifts in Idiopathic Pulmonary Fibrosis
  6. Population Analysis of T cell Subsets in Idiopathic Pulmonary Fibrosis
  7. Analysis of Lymphoid Cell Population Proportions in IPF Conditions
  8. Cell-Cell Interaction Pattern Analysis in Idiopathic Pulmonary Fibrosis (IPF)
  9. Condition-Specific Cell-Cell Interaction Patterns in Idiopathic Pulmonary Fibrosis
  10. T cell CD8+ Condition-Specific Surfaceome Marker Expression in Idiopathic Pulmonary Fibrosis
  11. Monocyte Condition-Specific Surfaceome Marker Expression Analysis in Idiopathic Pulmonary Fibrosis
  12. Surfaceome Marker Expression in CD4+ T Cells from Progressive Idiopathic Pulmonary Fibrosis
  13. Gene Ontology (GSA) Analysis of Monocytes across Idiopathic Pulmonary Fibrosis Conditions
  14. Gene Set Enrichment Analysis Across Blood Cell Types in Idiopathic Pulmonary Fibrosis
  15. Discussion
  16. Query List

0. Dataset overview

Dataset Summary

1. UMAP Visualization of Single-Cell Blood Transcriptome in Idiopathic Pulmonary Fibrosis

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Uniform Manifold Approximation and Projection (UMAP) plots derived from single-cell RNA-sequencing data of human blood. The dataset comprises 89619 cells and 21249 genes, obtained from individuals with different Idiopathic Pulmonary Fibrosis (IPF) conditions (control, progressive_ipf, stable_ipf). The UMAPs visualize the cellular embedding, colored by condition, individual sample, celltype_major, celltype_minor, and celltype_subset. These visualizations serve to evaluate the dataset's global structure, assess the quality of cell type annotations, and identify potential batch effects or condition-specific distributions of cell populations.

Visual Summary

Biological Interpretation

The UMAP visualizations of blood cells from IPF patients and controls offer critical insights into the dataset's quality and the potential impact of IPF on circulating immune cells.

  1. High-Resolution Cell Type Characterization: The excellent separation of cell populations across major, minor, and subset levels demonstrates the high quality and granularity of the cell type annotations. This robust cell type assignment is foundational for any subsequent differential analyses, allowing for precise identification of condition-specific changes within specific immune cell populations. The successful resolution of diverse blood cell types, including various T cell, B cell, ILC, and myeloid subsets, reflects the biological complexity captured by the single-cell RNA-seq data.
  2. Effective Integration and Minimized Batch Effects: The thorough intermixing of cells from different samples underscores the success of the data integration strategy. This reduces the risk of confounding batch effects influencing the biological interpretation, enabling more confident conclusions about disease-related cellular changes rather than technical variability.
  3. Subtle Condition-Associated Cellular Shifts: While no dramatic, condition-exclusive cell clusters are observed, the visible overlaps and subtle enrichments of specific conditions in certain UMAP regions suggest that IPF may induce quantitative changes in the composition of circulating immune cells or alter their transcriptional states. For instance, certain T cell or myeloid cell subsets might be expanded or activated/suppressed in progressive_ipf or stable_ipf compared to control. These observations align with the understanding that IPF involves systemic immune dysregulation that can impact peripheral blood cell profiles PMID: 31084206. Further differential abundance testing and cell-type-specific differential gene expression analyses will be crucial to statistically confirm and characterize these changes.

Annotation Notes

The presented UMAPs affirm the high quality of the single-cell dataset and its annotations. The clear hierarchical clustering of cell types, from broad categories to highly specific subsets, indicates robust cell identification. The minimal presence of unassigned cells further supports the comprehensiveness of the annotation. The successful integration across samples, with no apparent batch effects, suggests the dataset is well-prepared for downstream comparative analyses focused on the biological effects of IPF. The next steps should involve quantitative analysis of cell type proportions and gene expression changes to pinpoint the specific cellular alterations associated with IPF progression.

2. UMAP Visualization of Major Cell Type Scores and Annotations

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes major cell type scores, computed using HiCAT, on a Uniform Manifold Approximation and Projection (UMAP) embedding. The purpose is to evaluate how well the calculated cell type scores align with the existing celltype_major annotations and to identify potential additional populations or areas for annotation refinement within the single-cell RNA-seq data from human blood samples in the context of Idiopathic Pulmonary Fibrosis (IPF).

Visual Summary

The UMAP projection displays a clear separation of cellular populations. The celltype_major plot shows five primary annotated cell groups: T cells, Myeloid cells, B cells, Megakaryocytic cells, and an 'unassigned' category.

Additional Cell Type Scores:

Biological Interpretation

The strong concordance between the computed HiCAT_major_score values and the existing celltype_major annotations for key immune cell types (T cells, B cells, Myeloid cells, Megakaryocytic cells) provides robust validation for the initial cell type identification. This suggests that the transcriptomic profiles of these major cell populations are distinct and well-captured by the embedding.

The presence of distinct HiCAT_major_score signals for MDSC, Mast cells, and Erythroid cells, which are not explicitly included in the celltype_major column, is biologically significant. Myeloid-derived suppressor cells (MDSCs) and Mast cells are known to play roles in chronic inflammation and fibrotic diseases like IPF, and their identification in blood could indicate systemic immune dysregulation. Erythroid cells are expected in blood, and their clear identification by the score further confirms the quality of the data and analysis. The very low scores for Endothelial and Stromal cells align with the fact that the sample source is blood, not solid tissue, minimizing potential contamination from non-hematopoietic cells.

Annotation Notes

The HiCAT_major_score plots largely confirm the quality and accuracy of the existing celltype_major annotations for T cells, B cells, Myeloid cells, and Megakaryocytic cells, as their corresponding scores are highly concentrated within their respective annotated clusters.

The analysis also reveals opportunities for refining the existing annotations:

3. Marker Expression Dot Plot for Cell Subsets

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a marker expression dot plot, illustrating the expression patterns of identified marker genes across various fine-grained cell subsets (celltype_subset) in the provided single-cell RNA-seq dataset. Each row represents a celltype_subset, and each column represents a gene. The size of the dot corresponds to the fraction of cells within that group expressing the gene, while the color intensity indicates the mean expression level of the gene in that cell group. The primary goal of this visualization, as per the user query and interpretation priority, is to assess the quality and biological consistency of the assigned celltype_subset annotations by examining their respective marker gene expression profiles.

Visual Summary

The dot plot displays a matrix of marker gene expression across 24 distinct celltype_subset populations. The genes on the x-axis are grouped by the celltype_subset they are identified to mark, and red boxes highlight these expected primary expression patterns.

Biological Interpretation

The marker expression analysis serves as a critical quality control step for cell type annotation.

Well-Supported Annotations:

Annotations Requiring Further Scrutiny:

Annotation Notes

The celltype_subset annotations for major immune cell types and their well-established subsets (e.g., monocytes, NK cells, plasma cells, platelets, cytotoxic T cells) are strongly supported by the marker gene expression patterns displayed in this dot plot. The markers for these groups are largely canonical and show high specificity and expression within their respective populations.

However, the annotations for several T helper cell subsets (Th1, Th2, Th17, Tfh, Naive, Treg), as well as ILC2 and LTI, are less confidently supported by the marker genes presented. The identified markers for these specific subsets are either non-canonical, shared broadly across T cell populations, or, in the cases of Th1, Th17, and Th2, appear to contradict established biological roles of their master regulators and signaling pathways. This suggests that the marker discovery process (find_cfg) may not have identified the most appropriate or distinguishing markers for these groups, or that the initial clustering and annotation for these particular cell types may warrant further investigation and refinement. It is recommended to re-evaluate the T cell subset annotations using alternative marker sets or more specific annotation strategies, potentially incorporating flow cytometry data or knowledge-based marker lists to ensure accuracy.

4. Peripheral Blood Immune Cell Population Shifts in Idiopathic Pulmonary Fibrosis

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents the relative proportions of minor cell types identified in single-cell RNA-seq data from human blood samples. The primary objective is to evaluate potential alterations in immune cell composition across three distinct conditions: 'control' (healthy individuals), 'progressive_ipf' (patients with progressive Idiopathic Pulmonary Fibrosis), and 'stable_ipf' (patients with stable Idiopathic Pulmonary Fibrosis). These comparisons aim to elucidate systemic immune changes associated with IPF pathogenesis and disease progression.

Visual Summary

The stacked bar plots illustrate the proportional distribution of ten minor cell types across individual samples within each condition.

Biological Interpretation

The observed shifts in peripheral blood immune cell populations suggest significant systemic immune alterations in IPF patients.

Clinical or Translational Implications

These systemic immune profiling results from peripheral blood have several potential clinical and translational implications for IPF:

5. Population Analysis of T cell Subsets in Idiopathic Pulmonary Fibrosis

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the proportional distribution of various T cell subsets, NK cells, and Innate Lymphoid Cells (ILCs) within the major 'T cell' compartment across different conditions: control, progressive idiopathic pulmonary fibrosis (IPF), and stable IPF. The visualization is stratified by individual samples within each condition, providing insights into immune cell composition changes associated with disease status. The data is derived from single-cell RNA-seq of human blood samples.

Visual Summary

The stacked bar plots display the relative proportions of T cell (Naive), T cell (Cytotoxic), T cell (Treg), NK cells, and various ILC subsets (ILC1, ILC2, ILC3 (NCR+), ILC3 (NCR-), ILCreg, LTI), along with other T helper subsets (Tfh, Th1, Th17, Th2, Th22, Th9), and an 'unassigned' category.

Key observations include:

Biological Interpretation

The observed shifts in the peripheral blood T cell and ILC populations in IPF patients, especially those with progressive disease, point towards significant systemic immune dysregulation.

Clinical or Translational Implications

The distinct immune cell population shifts observed in the peripheral blood of IPF patients, particularly in progressive disease, hold several clinical and translational implications:

6. Analysis of Lymphoid Cell Population Proportions in IPF Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents box plots visualizing the proportions of various lymphoid cell populations, including T cell subsets, Natural Killer (NK) cells, and Innate Lymphoid Cells (ILCs), across three conditions: stable Idiopathic Pulmonary Fibrosis (stable_ipf), healthy controls (control), and progressive Idiopathic Pulmonary Fibrosis (progressive_ipf). The goal was to identify statistically significant differences in these cell proportions between conditions in peripheral blood samples. The statistical significance cutoff for p-values was set at 0.1.

Visual Summary

The box plots reveal several statistically significant differences in the proportions of specific lymphoid populations when comparing stable_ipf, control, and progressive_ipf conditions:

Treg (Regulatory T cells)

NK (Natural Killer cells)

Th22 (T helper 22 cells)

Th17 (T helper 17 cells)

Th2 (T helper 2 cells)

ILCreg (Regulatory Innate Lymphoid Cells)

LTI (Lymphoid Tissue Inducer cells)

T_Naive (Naive T cells)

Biological Interpretation

These findings highlight notable shifts in peripheral blood lymphoid cell composition in Idiopathic Pulmonary Fibrosis (IPF) patients, particularly differentiating between stable and progressive disease states, and healthy controls. The observed changes suggest dysregulation of both adaptive and innate immune responses, which can significantly influence disease pathogenesis.

  1. Increased Immunosuppression/Dysregulation in Progressive IPF: The most striking finding is the significant increase in Treg cells in progressive IPF compared to stable IPF and controls. Regulatory T cells are crucial for maintaining immune tolerance and suppressing excessive immune responses. While their increase might be a compensatory mechanism to dampen inflammation, dysregulated or phenotypically altered Tregs can also directly promote fibrosis or fail to resolve pathogenic inflammation in fibrotic diseases like IPF [1, 2].
  2. Altered Inflammatory and Repair Responses:
  1. Innate Immune System Dysregulation:
  1. T Cell Exhaustion/Differentiation: The lower proportion of T_Naive cells in stable IPF compared to controls might indicate increased T cell activation, differentiation, or exhaustion, potentially driven by chronic antigen exposure or inflammatory signals in the disease environment.

Clinical or Translational Implications

The observed changes in lymphoid cell proportions in peripheral blood provide valuable insights into the immune landscape of IPF and hold potential for clinical applications:

References:

  1. Treg cells in fibrosis: PubMed search for "Treg cells fibrosis IPF"
  2. Treg role in IPF: GeneCards: FOXP3 (FOXP3 is a key marker for Tregs)
  3. Th22 cells and IL-22 in lung disease: PubMed search for "Th22 cells IL-22 lung fibrosis"
  4. Th2 cells and fibrosis: PubMed search for "Th2 cells fibrosis IPF"
  5. NK cells in IPF: PubMed search for "NK cells IPF"
  6. Immunomodulation in IPF: PubMed search for "immunomodulation IPF therapy"

7. Cell-Cell Interaction Pattern Analysis in Idiopathic Pulmonary Fibrosis (IPF)

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interaction (CCI) patterns in peripheral blood mononuclear cells across different conditions related to Idiopathic Pulmonary Fibrosis (IPF): control, progressive_ipf, and stable_ipf. Using CellPhoneDB, ligand-receptor interactions between various immune cell types (T cells, Monocytes, NK cells, B cells) have been computed and visualized. The results highlight the top 80 most significant cell-cell interactions for each condition, providing insights into potential immune dysregulation and communication changes in IPF patients compared to healthy controls, and differentiating between progressive and stable disease states.

Visual Summary

The dot plots display cell-cell interactions, where the y-axis represents interacting cell pairs and the x-axis represents specific ligand-receptor gene pairs. The size of each dot correlates with the statistical significance of the interaction (-log10(p-value)), and the color intensity indicates the mean expression level of the interacting ligand-receptor pair (log2(mean)).

  1. Overall Activity: There is a noticeable increase in the number and intensity of significant cell-cell interactions from control to stable_ipf, and further to progressive_ipf. This suggests a heightened state of immune cell communication and activation in IPF, particularly in the progressive form of the disease.
  2. Dominant Cell Types: Monocytes and T cells (CD4+ and CD8+) are frequently involved in the most significant interactions across all conditions, with Monocyte-Monocyte and Monocyte-T cell interactions being particularly prominent in IPF conditions.
  3. Key Interaction Pathways in IPF:
  1. Condition-Specific Differences:

Biological Interpretation

The observed shifts in cell-cell interaction patterns in the blood of IPF patients, particularly the heightened activity in progressive_ipf, provide critical insights into the systemic immune environment associated with the disease.

These systemic blood-based CCI patterns likely reflect the broader immune dysregulation occurring in IPF, with specific interactions potentially driving disease progression or acting as indicators of disease activity.

Clinical or Translational Implications

The findings from this cell-cell interaction analysis offer several important clinical and translational implications:

8. Condition-Specific Cell-Cell Interaction Patterns in Idiopathic Pulmonary Fibrosis

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interactions (CCIs) among major immune cells (T cells, Myeloid cells, and B cells) in peripheral blood, comparing individuals with progressive Idiopathic Pulmonary Fibrosis (IPF), stable IPF, and healthy controls. The plot_dot_for_cci_with_signif_difference tool was used to identify and visualize the top 60 most significant CCIs within each condition, based on interaction strength and statistical significance (p-value). The dot plot displays these interactions per sample, with dot color indicating scaled log interaction strength and dot size representing the -log10(p-value) of the interaction.

Visual Summary

The dot plot reveals distinct and shared patterns of cell-cell interactions across the 'control', 'progressive_ipf', and 'stable_ipf' conditions.

Condition-Specific Prominence:

Biological Interpretation

The observed condition-specific patterns of cell-cell interactions in the blood provide insights into systemic immune alterations in IPF.

  1. Elevated Prostaglandin E2 (PGE2) Signaling in Progressive IPF:
  1. Persistent Integrin-Mediated Adhesion in IPF:
  1. Altered Co-stimulatory and Inhibitory Signaling:
  1. Prominent "Don't Eat Me" Signaling via SIRPG_CD47 in Progressive IPF:
  1. Differential B cell-T cell Interactions (FCER2_CR2) in IPF:

Clinical or Translational Implications

The identification of specific cell-cell interactions that differ across IPF conditions, even in peripheral blood, provides potential avenues for therapeutic intervention and biomarker discovery.

9. T cell CD8+ Condition-Specific Surfaceome Marker Expression in Idiopathic Pulmonary Fibrosis

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes condition-specific surfaceome markers for CD8+ T cells from single-cell RNA sequencing data of human blood. The study investigates three conditions: control, progressive Idiopathic Pulmonary Fibrosis (IPF), and stable IPF. The goal is to highlight differential surface marker expression patterns that could provide insights into disease mechanisms and potential therapeutic targets, specifically focusing on the T cell CD8+ population. The dot plot displays the fraction of cells expressing a marker (dot size) and the mean expression level within those cells (dot color intensity) for selected surface markers across individual samples grouped by condition.

Visual Summary

The dot plot visualizes the expression of ten key surface markers across various individual samples, categorized into three conditions: control (C samples), progressive IPF (P samples), and stable IPF (S samples).

Overall, the plot clearly delineates distinct surfaceome profiles for CD8+ T cells across the three conditions, suggesting condition-specific immunological states.

Biological Interpretation

The observed surface marker expression patterns in CD8+ T cells offer crucial insights into their functional states and roles in IPF pathogenesis.

KLRB1 (CD161) in Control Samples:

CD27 and TIGIT in Progressive IPF Samples:

Signaling Pathways/Biological Mechanisms:

S1PR1 in Progressive IPF Samples:

HLA-DRB5, CD320, FCGR3A, PTGDR, and CXCR3 in Stable IPF Samples:

Signaling Pathways/Biological Mechanisms:

Clinical or Translational Implications

The distinct CD8+ T cell surface marker profiles across control, progressive, and stable IPF conditions offer potential avenues for diagnostic, prognostic, and therapeutic development in IPF.

Biomarkers for Disease Progression:

Therapeutic Targets:

Further studies are needed to confirm the functional implications of these surface markers in IPF pathogenesis and to validate their utility as biomarkers or therapeutic targets within the specific context of lung tissue, given that this analysis is based on blood samples.

10. Monocyte Condition-Specific Surfaceome Marker Expression Analysis in Idiopathic Pulmonary Fibrosis

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surfaceome markers in Monocytes across 'control' and 'stable_ipf' conditions using single-cell RNA sequencing data from blood tissue. The goal is to highlight surface markers that differentiate monocyte subsets in stable IPF from healthy controls, providing insights into potential underlying biological mechanisms and therapeutic targets. The plot_markers_and_expression_dot tool was used to visualize marker expression, focusing on highly expressed surfaceome genes in at most 40 markers per condition, utilizing nz_pct_score and fc_cutoff for marker selection.

Visual Summary

The dot plot displays the expression of five surfaceome markers (CD83, PTGER4, HLA-DQA2, C3AR1, AQP9) across various monocyte clusters, comparing 'control' and 'stable_ipf' conditions.

Differential Expression Patterns:

Biological Interpretation

The observed differential expression of surfaceome markers on monocytes in the blood provides critical insights into immune dysregulation in Idiopathic Pulmonary Fibrosis (IPF).

  1. Reduced CD83 and PTGER4 in Stable IPF Monocytes (Control-associated clusters):
  1. Upregulated HLA-DQA2, C3AR1, and AQP9 in Stable IPF Monocytes (IPF-associated clusters):

Clinical or Translational Implications

The identified surfaceome markers in monocytes offer potential avenues for understanding IPF pathogenesis and developing targeted therapies.

Therapeutic Targets

Further research focusing on the functional consequences of these marker changes in IPF monocytes, particularly within the lung microenvironment, is warranted to validate their roles as diagnostic tools or therapeutic targets.

---

References:

  1. PTGER4 (EP4) and IPF: Search PubMed for "EP4 IPF therapy" to explore research on EP4 as a therapeutic target in pulmonary fibrosis. PubMed Search: EP4 IPF therapy
  2. HLA-DQA2 in Immune Responses: Learn more about MHC Class II molecules and their role in antigen presentation from resources like GeneCards. GeneCards: HLA-DQA2
  3. C3AR1 and Complement in Disease: For information on C3AR1 and its involvement in inflammatory processes, consult GeneCards or UniProt. GeneCards: C3AR1

11. Surfaceome Marker Expression in CD4+ T Cells from Progressive Idiopathic Pulmonary Fibrosis

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes surfaceome marker expression specifically within CD4+ T cells from individuals with progressive Idiopathic Pulmonary Fibrosis (IPF). The objective is to highlight key surface proteins that are robustly expressed in this cell type under the specified disease condition, providing insights into their potential biological roles and therapeutic relevance. The visualization is a dot plot, where dot size indicates the fraction of cells expressing a marker, and dot color represents the mean expression level within the group.

Visual Summary

The dot plot displays the expression profiles of identified surfaceome markers for CD4+ T cells in the progressive_ipf condition. While the plot lists numerous markers, the discernible gene symbols at the bottom of the provided visualization are PTGER2 and SIT1.

For both PTGER2 and SIT1, the visualization shows:

These observations indicate that PTGER2 and SIT1 are prominent and widely expressed surfaceome proteins on CD4+ T cells in the context of progressive IPF.

Biological Interpretation

The robust expression of PTGER2 and SIT1 on CD4+ T cells in progressive IPF patients suggests their significant involvement in the immune landscape of this disease.

PTGER2 (Prostaglandin E Receptor 2)

SIT1 (SHP2 Interacting Transmembrane Adaptor Protein 1)

Clinical or Translational Implications

The identification of PTGER2 and SIT1 as highly expressed surfaceome markers on CD4+ T cells in progressive IPF patients offers potential avenues for therapeutic intervention, though further functional validation is required.

PTGER2 as a Therapeutic Target

SIT1 as a Therapeutic Target

12. Gene Ontology (GSA) Analysis of Monocytes across Idiopathic Pulmonary Fibrosis Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This report presents the results of Gene Ontology (GO) enrichment analysis (GSA) for Monocytes, comparing each of the three conditions ('control', 'progressive_ipf', 'stable_ipf') against the other two combined (referred to as 'others'). The analysis identifies GO terms (pathways/biological processes) that are significantly enriched for upregulated genes within Monocytes in the specified condition. The results are visualized as bar plots, showing the top enriched terms ranked by their -log(p-val) and -log(q-val). A higher -log(p-val) and -log(q-val) indicates greater statistical significance of enrichment.

Visual Summary

The analysis provides three distinct bar plots, each focusing on Monocytes from a specific condition:

  1. GSA_up for Monocyte: control_vs_others: This plot displays GO terms significantly enriched in control monocytes compared to the combined progressive and stable IPF monocytes. The most significant terms include "Spliceosome", "Huntington disease", "Pathways of neurodegeneration", "Proteasome", and "Protein processing in endoplasmic reticulum", alongside several fundamental cellular processes and pathogen-related terms.
  2. GSA_up for Monocyte: progressive_ipf_vs_others: This plot highlights GO terms significantly enriched in progressive IPF monocytes compared to control and stable IPF monocytes. Top enriched terms include "Ribosome", "Coronavirus disease", "Diabetic cardiomyopathy", "Non-alcoholic fatty liver disease", "Chemokine signaling pathway", and "Leukocyte transendothelial migration". These indicate a shift towards inflammatory and migratory activities.
  3. GSA_up for Monocyte: stable_ipf_vs_others: This plot shows GO terms significantly enriched in stable IPF monocytes compared to control and progressive IPF monocytes. Highly enriched terms include "Shigellosis", "Endocytosis", "NOD-like receptor signaling pathway", "Yersinia infection", "Salmonella infection", "Lipid and atherosclerosis", and "Chemokine signaling pathway". These suggest active innate immune responses and cellular uptake.

Across all plots, a range of infectious disease pathways (e.g., Salmonella, Epstein-Barr virus, Influenza A, Coronavirus disease) and neurodegenerative pathways (e.g., Alzheimer disease, Parkinson disease, Huntington disease) appear frequently, albeit with varying degrees of significance across conditions.

Biological Interpretation

Monocytes are crucial innate immune cells that circulate in the blood and can differentiate into macrophages and dendritic cells, playing vital roles in immune surveillance, inflammation, and tissue repair. The observed differential enrichment of GO terms suggests distinct functional states of circulating monocytes across different IPF conditions.

Monocyte Profiles by Condition:

Control Monocytes (enriched in control vs. combined IPF states):

Monocytes from control individuals show significant enrichment in fundamental cellular processes such such as the Spliceosome, Proteasome, Ribosome, Protein processing in endoplasmic reticulum, RNA transport, Oxidative phosphorylation, and Citrate cycle (TCA cycle). This suggests that in a healthy, homeostatic state, circulating monocytes maintain robust basic cellular machinery, indicating efficient metabolic activity, protein synthesis, and degradation pathways. Enrichment in Antigen processing and presentation and Phagosome terms further reflects their baseline immune surveillance and antigen-presenting functions, which are critical for initiating adaptive immune responses. The prominence of neurodegenerative disease-related pathways might reflect fundamental cellular maintenance or stress response pathways that are less perturbed in healthy cells compared to disease states.

Monocytes in progressive IPF exhibit a profile strongly indicative of activation and increased migratory potential. Highly enriched terms like Chemokine signaling pathway and Leukocyte transendothelial migration are particularly notable. These pathways are central to immune cell recruitment and extravasation from the bloodstream into tissues, suggesting that monocytes in progressive IPF are primed to migrate to sites of inflammation and fibrosis in the lung. This is consistent with the known role of monocytes differentiating into pro-fibrotic macrophages that drive disease progression in IPF. The enrichment of Ribosome and Oxidative phosphorylation also points to increased metabolic activity and protein synthesis, characteristic of activated immune cells undergoing functional changes. The term "Osteoclast differentiation" might suggest a shift towards distinct myeloid differentiation programs, potentially contributing to tissue remodeling.

Monocytes in stable IPF show enrichment in innate immune response pathways, including NOD-like receptor signaling pathway, NF-kappa B signaling pathway, Phagosome, and Autophagy. This suggests a heightened state of innate immune sensing, pathogen recognition, and cellular clearance mechanisms, potentially involved in sustaining a chronic inflammatory response. Endocytosis and Lysosome enrichment further supports active cellular uptake and degradation, which are critical functions for monocytes/macrophages in clearing debris and pathogens. The presence of Chemokine signaling pathway also indicates ongoing inflammatory communication and potential recruitment, though the specific types or magnitude might differ from the progressive phase. The high prevalence of various infectious disease terms across all conditions, including in stable IPF, could reflect a general inflammatory milieu or a heightened immune response to potential infections in the context of chronic lung disease.

Overall Interpretation:

The findings suggest a dynamic shift in monocyte biology during IPF. In progressive IPF, monocytes appear to be highly activated for migration and inflammatory signaling, potentially contributing to the worsening fibrotic process. In stable IPF, monocytes demonstrate a robust innate immune response and cellular clearance phenotype, which might play a role in maintaining disease stability or responding to chronic stimuli. Control monocytes, in contrast, emphasize homeostatic cellular functions and baseline immune surveillance. The common enrichment of certain infectious disease and neurodegenerative pathways across conditions might reflect general systemic inflammatory responses or shared cellular stress pathways that are dysregulated in the context of IPF.

Clinical or Translational Implications

The distinct functional profiles of monocytes observed across control, stable IPF, and progressive IPF conditions hold significant clinical and translational implications:

References:

13. Gene Set Enrichment Analysis Across Blood Cell Types in Idiopathic Pulmonary Fibrosis

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results for various celltype_minor populations in blood, comparing different disease conditions (control, progressive_ipf, stable_ipf) against the combined "other" conditions. The dot plot visualizes the Normalized Enrichment Score (NES) using color (red for positive enrichment, blue for negative enrichment) and the significance (-log(p-value)) using dot size. The objective is to identify key pathways and biological processes that are differentially regulated in specific immune cell subsets during stable and progressive Idiopathic Pulmonary Fibrosis (IPF).

Visual Summary

The GSEA dot plot reveals distinct patterns of pathway enrichment and depletion across various blood cell types (B cell, Granulocyte, ILC, Monocyte, NK cell, Plasma cell, Platelet, T cell CD4+, T cell CD8+) and conditions related to IPF.

Key Enriched Pathways:

Biological Interpretation

The observed GSEA patterns provide insights into the systemic immune dysregulation in IPF, particularly in its progressive form. The study being conducted on blood samples allows for the detection of circulating immune cell alterations that may reflect or contribute to lung pathology.

  1. Exaggerated Inflammation and Immune Cell Recruitment: The strong enrichment of the Chemokine signaling pathway across multiple immune cell types, especially in progressive IPF, indicates enhanced chemokine production and responsiveness. Chemokines are crucial for immune cell recruitment to sites of inflammation and fibrosis, suggesting increased trafficking of these cells towards the affected lung tissue in IPF [PubMed Search: chemokines IPF fibrosis]. Similarly, the upregulation of Leukocyte transendothelial migration supports this notion of increased migratory potential of immune cells.
  2. Innate and Adaptive Immune Activation:
  1. Metabolic Reprogramming and Cellular Stress: The activation of metabolic pathways like Fatty acid elongation and Lysosome in Monocytes and NK cells suggests metabolic reprogramming, which is a common feature of activated immune cells and plays a role in their effector functions [PubMed Search: immune cell metabolism fibrosis]. Upregulation of Apoptosis pathways might reflect increased cellular turnover, chronic stress-induced cell death, or an attempt to resolve inflammation.
  2. Dysregulated Growth and Survival Signaling: The consistent enrichment of the mTOR signaling pathway is highly relevant. mTOR is a central regulator of cell growth, proliferation, metabolism, and survival, and its hyperactivation is implicated in various fibrotic diseases, including IPF, by promoting fibroblast activation and survival of immune cells [PubMed Search: mTOR signaling IPF fibrosis].

Clinical or Translational Implications

The findings from this GSEA analysis have several potential clinical and translational implications for IPF:

14. Discussion

This comprehensive single-cell analysis of peripheral blood in Idiopathic Pulmonary Fibrosis (IPF) provides compelling evidence of systemic immune dysregulation that correlates with disease progression. While UMAP visualizations confirm robust cell type annotation and data integration, the subsequent in-depth analyses highlight significant shifts in cell population proportions, surface marker expression, cell-cell interactions, and pathway enrichment, offering critical insights into IPF pathogenesis.

A central finding is the consistent monocytosis observed in both stable and progressive IPF, accompanied by a relative reduction in circulating T cells. Monocytes in progressive IPF exhibit a strong transcriptional signature of activation, with Gene Ontology analysis revealing enrichment in 'Chemokine signaling pathway' and 'Leukocyte transendothelial migration', indicating their priming for migration to inflammatory sites. This is further supported by Gene Set Enrichment Analysis, which shows broad immune activation and upregulation of the mTOR pathway across monocytes, NK cells, and T cells in progressive IPF. In contrast, stable IPF monocytes show enrichment in innate immune sensing ('NOD-like receptor signaling pathway', 'NF-kappa B signaling pathway') and cellular clearance ('Phagosome', 'Autophagy') pathways, suggesting a different, potentially more contained, inflammatory or adaptive response state. The differential expression of surface markers on monocytes further delineates these states: stable IPF monocytes upregulate HLA-DQA2 (suggesting enhanced antigen presentation) and C3AR1 (complement activation), while control monocytes show higher CD83 and PTGER4 (immune regulation/PGE2 responsiveness).

T cell populations also undergo significant alterations. Progressive IPF is marked by an increase in T regulatory cells (Tregs) and Th22 cells, while stable IPF shows increased NK cells but decreased Th17 and Th2 cells compared to controls. The reduction in naive T cells across IPF conditions suggests chronic immune activation and differentiation. At the surfaceome level, CD8+ T cells in progressive IPF conspicuously co-express CD27 (activation/memory) and TIGIT (exhaustion marker), alongside S1PR1 (lymphocyte egress), pointing to a state of activated but potentially exhausted T cell responses that may fail to effectively resolve inflammation or contribute to tissue damage. Conversely, CD8+ T cells in stable IPF upregulate HLA-DRB5, FCGR3A, and CXCR3, indicating a highly activated, tissue-homing, and potentially cytotoxic phenotype. CD4+ T cells in progressive IPF show high expression of PTGER2 (PGE2 receptor) and SIT1 (TCR inhibitor), suggesting they are subject to immunomodulatory and inhibitory signals.

Cell-cell interaction (CCI) analyses reveal a progressively heightened communication network from control to stable to progressive IPF, notably centered around monocytes. Key interactions in progressive IPF include SPP1-integrin αVβ1 (a potent pro-fibrotic axis), CXCL12-CXCR4 (critical for immune cell trafficking), SIRPG-CD47 ('don't eat me' signal, potentially hindering clearance of senescent cells), and sustained PGE2 receptor signaling. These interactions underscore enhanced systemic inflammation, cellular trafficking, and altered immune regulation, which likely contribute to the fibrotic milieu. The prevalence of CD86-CD28 interactions in progressive IPF further highlights ongoing T cell co-stimulation.

In summary, the peripheral blood in progressive IPF presents a highly activated, migratory, and potentially exhausted immune landscape, characterized by dysregulated monocyte and T cell functions and exacerbated cell-cell communication. These systemic changes are likely reflective of, and potentially contribute to, the chronic inflammation and aberrant repair mechanisms occurring in the fibrotic lung. The distinct profiles observed between stable and progressive IPF, and healthy controls, offer valuable targets for therapeutic intervention and biomarkers for disease monitoring.

Hypotheses:

  1. Expanded and activated monocytes in progressive IPF drive fibrotic processes through increased trafficking, antigen presentation (HLA-DQA2), and complement-mediated inflammation (C3AR1).
  2. CD8+ T cells in progressive IPF are in a state of exhaustion (TIGIT+) that impairs effective anti-fibrotic immunity and contributes to disease persistence.
  3. Dysregulated PGE2 signaling, particularly via PTGER2/PTGER4 on CD4+ T cells and monocytes, contributes to immune suppression or aberrant immune responses in progressive IPF, failing to resolve inflammation.
  4. Enhanced cell-cell interactions, specifically involving SPP1-integrin and CXCL12-CXCR4 axes, promote the recruitment and activation of pro-fibrotic immune cells to the lung in progressive IPF.
  5. The 'don't eat me' signal via SIRPG-CD47 is amplified in progressive IPF, potentially impairing the clearance of senescent cells or apoptotic debris that perpetuate inflammation and fibrosis.

Potential therapeutic targets:

  1. TIGIT (on CD8+ T cells): High expression of TIGIT on CD8+ T cells in progressive IPF suggests a state of T cell exhaustion, which prevents effective anti-fibrotic or immune-regulatory responses. Blocking TIGIT could reinvigorate these T cells. Evidence: Section 9: TIGIT is consistently highly expressed on CD8+ T cells in progressive IPF samples. TIGIT acts as an inhibitory immune checkpoint receptor, leading to T cell exhaustion. Validation: Evaluate the effect of anti-TIGIT antibodies on the proliferation, cytokine production, and cytotoxic function of isolated CD8+ T cells from progressive IPF patients *in vitro*. Assess the impact of TIGIT blockade in relevant *in vivo* fibrosis models.
  2. C3AR1 (on Monocytes): Upregulation of C3AR1 on monocytes in stable IPF indicates increased responsiveness to complement component C3a, a potent pro-inflammatory mediator. Inhibiting this receptor could dampen monocyte-driven inflammation. Evidence: Section 10: HLA-DQA2, C3AR1, and AQP9 are upregulated in stable IPF monocytes. C3AR1 is a receptor for complement anaphylatoxin C3a, leading to cell activation and cytokine release. Validation: Test C3AR1 antagonists on isolated stable IPF monocytes *in vitro* for their ability to reduce pro-inflammatory cytokine secretion and migratory capacity. Evaluate the therapeutic potential of C3AR1 inhibitors in pre-clinical models of pulmonary fibrosis.
  3. SPP1-Integrin αVβ1 Axis (Monocyte-centric CCIs): The SPP1 (Osteopontin)-integrin αVβ1 interaction is highly significant and strongly expressed in progressive IPF, particularly among monocytes and T cells. SPP1 is a known pro-fibrotic cytokine that promotes fibroblast activation and immune cell recruitment. Blocking this axis could directly target fibrosis-driving mechanisms. Evidence: Section 7: SPP1-integrin αVβ1 complex is highly significant and strongly expressed in progressive IPF for various cell pairs, notably Monocyte-Monocyte and Monocyte-T cell CD8+/CD4+. Section 8 reiterates its significance. Validation: Use neutralizing antibodies against SPP1 or integrin αV/β1 to disrupt these interactions in *in vitro* co-culture systems of IPF-derived monocytes and fibroblasts, assessing effects on fibroblast activation and collagen production. Test efficacy in relevant animal models of pulmonary fibrosis.
  4. CXCR3/CXCL10 Axis (T cell/Monocyte trafficking): CXCR3 is elevated on CD8+ T cells in stable IPF, and chemokine signaling pathways, including CXCL10, are broadly enriched in progressive IPF across multiple cell types. This axis is critical for recruiting immune cells to inflammatory sites. Blocking CXCR3 could limit the infiltration of pathogenic immune cells into the fibrotic lung. Evidence: Section 9: CXCR3 shows strong expression on CD8+ T cells in stable IPF. Section 13: Chemokine signaling pathway shows consistent and strong positive enrichment across B cells, Granulocytes, Monocytes, NK cells, T cell CD4+, and T cell CD8+ in progressive IPF. Validation: Employ CXCR3 antagonists *in vitro* to assess their impact on the migratory capacity of IPF-derived T cells and monocytes. Evaluate the effect of CXCR3/CXCL10 blockade on immune cell infiltration and fibrosis progression in experimental models of IPF.
  5. mTOR signaling pathway: The mTOR signaling pathway is consistently upregulated across multiple immune cell types (monocytes, NK cells, T cells) in progressive IPF. mTOR is a key regulator of cell growth, metabolism, and survival, and its hyperactivation promotes fibrosis. Inhibiting mTOR could broadly attenuate pro-fibrotic and pro-inflammatory responses. Evidence: Section 13: mTOR signaling pathway is consistently upregulated in Monocytes, NK cells, T cell CD4+, and T cell CD8+ in progressive IPF. Validation: Test existing mTOR inhibitors (e.g., rapamycin analogs) on isolated IPF immune cells for effects on proliferation, cytokine production, and metabolic reprogramming. Evaluate the efficacy of mTOR inhibitors in pre-clinical models of IPF, assessing their impact on immune cell phenotype and fibrotic markers.

Follow-up validation ideas:

  1. Perform multi-parameter flow cytometry on peripheral blood and bronchoalveolar lavage fluid (BALF) from IPF patients to validate the altered proportions of T cell subsets (Tregs, Th22, T_Naive), NK cells, and the expression of surface markers like TIGIT, CD27, HLA-DQA2, C3AR1, and CXCR3 on specific cell populations.
  2. Conduct functional *in vitro* assays using isolated monocytes and T cells from IPF patients to assess migratory capacity (chemotaxis assays), cytokine production profiles, antigen-presenting function, and T cell activation/exhaustion status in response to specific stimuli or therapeutic agents.
  3. Utilize spatial transcriptomics or multiplexed immunostaining on IPF lung biopsy samples to validate the presence, localization, and co-localization of cell types with observed peripheral blood changes (e.g., TIGIT+ CD8+ T cells, C3AR1+ monocytes) and to confirm the activity of key cell-cell interactions (e.g., SPP1-integrin) within the fibrotic microenvironment.
  4. Develop *in vitro* perturbation models using primary human IPF-derived cells or relevant cell lines to test the impact of targeting identified therapeutic pathways (e.g., TIGIT blockade, C3AR1 antagonism, PGE2 pathway modulation, mTOR inhibition) on pro-fibrotic gene expression, cell survival, and inflammatory responses.
  5. Validate the identified biomarkers and therapeutic targets in an independent, larger cohort of IPF patients, including longitudinal sampling, to correlate peripheral blood findings with clinical progression, lung function decline, and treatment response.

Limitations:

This report is based on single-cell RNA sequencing data from peripheral blood, meaning the observed systemic immune changes may not fully recapitulate the complex cellular dynamics and microenvironment within the primary affected organ, the lung. The interpretations of cell population shifts and gene expression patterns are correlative and do not establish direct causality in IPF pathogenesis. Furthermore, while most cell type annotations are robust, the marker gene expression for some T helper cell subsets displayed inconsistencies, suggesting potential refinement opportunities for these specific annotations. The heterogeneity within patient groups, particularly 'stable_ipf', also highlights the diverse nature of IPF, implying that findings may not apply uniformly to all patients. The surfaceome marker analysis was limited to a subset of markers and may not capture all relevant surface proteins. Finally, the analysis infers disease context from metadata, which is not a clinical diagnosis or observation from this particular dataset.

15. Query List

  1. Show and save UMAPs for condition, sample, major cell type, minor cell type, and celltype_subset in two columns.
  2. Show major cell type scores on UMAP and save the result.
  3. Show and save a marker expression dot plot for celltype_subset. SET target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values.
  4. Show and save a population bar plot of minor cell types.
  5. Show and save a population bar plot of T cell subsets.
  6. Show and save box plots of T cell subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
  7. Show and save cell-cell interaction patterns. Select at most 80 cell-cell interactions per group.
  8. Find cell-cell interactions involving major immune and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms and, where relevant, its potential as a therapeutic target and related therapeutic agents.
  9. Show marker expressions for T cell CD8+ in a dot plot, and save the result. Use only surfaceome markers, with at most 50 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the tissue and, where relevant, its potential as a therapeutic target for Idiopathic Pulmonary Fibrosis and related therapeutic agents.
  10. Show marker expressions for Monocyte in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the tissue and, where relevant, its potential as a therapeutic target for Idiopathic Pulmonary Fibrosis and related therapeutic agents.
  11. Show marker expressions for T cell CD4+ in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the tissue and, where relevant, its potential as a therapeutic target for Idiopathic Pulmonary Fibrosis and related therapeutic agents.
  12. Show Gene Ontology (GSA) analysis results for Monocyte as a bar plot, and save the result.
  13. Show Gene Set Enrichment Analysis results as a dot plot, and save it. Set the color map to RdBu_r, n_pws_to_show to 120, and target_cells to None.
↑ Top